American biopharmaceutical company Neurocrine Biosciences recently acquired Diurnal, a UK-headquartered specialty pharmaceutical company dedicated to developing lifelong treatments for rare and chronic endocrine disorders and Myles Minter shared with MedCity News, a biotech industry trade publication, the implications for the company and it’s shareholders.
Equity Research
Myles Minter Analyzes Biotech Industry Acquisition in MedCity News
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
Inari Medical, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Inari Medical, Inc. (NARI $54.73), a medical device company that develops interventional products for patients suffering from venous diseases.
Read moreGifting Appreciated Securities to a Donor-Advised Fund Program
This charitable vehicle provides a simplified approach that allows you to maximize your charitable donations and tax benefits—an approach that can transform the way you give.
Read moreClio Valued at $3B in $900M Series F Investment Led by NEA
William Blair acted as the exclusive financial advisor to Clio in connection with its $900 million Series F investment round led by New Enterprise Associates, at a $3.0 billion valuation.
Read more